MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Agenus Cash Conversion Cycle 2011-2026 | AGEN
Annual Cash Conversion Cycle Agenus
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -25.8 K | -46.2 K | -6 K | -1.23 K | -2.5 K | -2.34 K | 10.2 | -30.4 | -15.5 | 163 | 121 | -26.4 | -22.4 | -7.47 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 163 | -46.2 K | -5.99 K |
Quarterly Cash Conversion Cycle Agenus
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.3 K | -26 K | -41.9 K | - | -30.2 K | -40.3 K | -47.8 K | - | -14.1 K | -17.8 K | -1.74 K | - | -11.9 K | -1.66 K | -5.46 K | - | -2.47 K | -2.63 K | -1.49 K | 3.38 | -1.7 K | -2.45 K | 52.6 | 43.1 | 74.6 | 94.6 | 9.84 | 13.3 | 6.69 | 5.38 | 57.8 | 12.4 | 30.8 | 24.6 | 21.1 | 186 | 233 | 157 | 162 | 117 | 131 | 140 | 118 | 26.1 | 27 | 13.7 | 29.4 | 0.28 | 0.15 | 0.14 | 22.8 | 46.2 | 58 | 80.4 | 1.88 | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 233 | -47.8 K | -5.08 K |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K |  USA |
 |
Alnylam Pharmaceuticals
ALNY
|
46.6 | $ 327.0 | -1.92 % | $ 42.8 B | USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
205 | $ 21.94 | 1.2 % | $ 1.03 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
-1.83 K | - | -5.16 % | $ 5.39 M | USA |
 |
Akebia Therapeutics
AKBA
|
42 | $ 1.4 | -10.0 % | $ 360 M | USA |
 |
Aquestive Therapeutics
AQST
|
-172 | $ 4.22 | -0.59 % | $ 451 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
158 | $ 24.2 | -1.55 % | $ 3.08 B | USA |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 8.59 | -1.1 % | $ 6.83 B |  Spain |
 |
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
340 | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
119 | $ 1.53 | 2.68 % | $ 407 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Caladrius Biosciences
CLBS
|
164 | - | -16.75 % | $ 25.8 M | USA |
 |
Clearside Biomedical
CLSD
|
-1.67 K | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
-3.74 K | $ 33.66 | -0.62 % | $ 2.24 B | USA |
 |
bluebird bio
BLUE
|
-54.4 | - | - | $ 546 M | USA |